Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ?

Medical Hypotheses

Volumn 74, Issue 3, 2010, Pages 613-614

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^c  

^a Fountain Medical Court ^*  (United States)

^b Comando Brigata alpina Julia ^*  (Italy)

^c Ospedale Civile di Tolmezzo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; PRAVASTATIN;

BREAST CANCER; BREAST CARCINOMA; BREAST LESION; CARCINOMA IN SITU; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG USE; ENZYME ACTIVATION; EPITHELIUM CELL; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LETTER; RACE DIFFERENCE; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

BREAST NEOPLASMS; CARCINOMA IN SITU; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 77649271266     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.10.016     Document Type: Letter

References (5)

1. Sprague B.L., Trentham-Dietz Prevalence of breast carcinoma in situ in the United States. JAMA 2009, 302:846-848.
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. For the cholesterol and recurrent events trial investigators. N Engl J Med 1996, 335:1001-1009.
3. Merla R., Ye Y., Lin Y., et al. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol 2007, 293:1918-1928.
4. Pearson G.W., Hunter T. PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture. Breast Cancer Res 2009, 11:R29.
5. Mann D., Reynolds K., Smith D., Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008, 42:1208-1215.